\n\nExplanatory Note:\n\n
This Report on Form 8-K/A amends the\nCurrent Report on Form 8-K filed by the registrant on June 23, 2010 to\ncorrect information contained in Item 5.02, which is restated in its\nentirety.\n\n
Item 5.02 DEPARTURE OF DIRECTORS\nOR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS;\nCOMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.\n\n
(d) On June 18, 2010, Brady\nCorporation (the “Corporation”) announced that Gary S. Balkema will\njoin the Corporation’s Board of Directors, effective July 19, 2010.\nThere was no arrangement or understanding pursuant to which Mr. Balkema\nwas appointed director, and no related party transactions exist between the\nCorporation and Mr. Balkema.\n\n
Mr. Balkema has not been appointed\nto any committees of the Board of Directors at this time. Upon becoming a\ndirector, he will be eligible to participate in the Corporation’s equity\nincentive and other benefit plans on a basis similar to other non-employee\ndirectors and, as such, will receive a stock option award of 10,000 shares\n14 days after he becomes a director.\n\n
A copy of the press release related to\nthe appointment of Mr. Balkema to the Board of Directors is being provided\nto the Securities and Exchange Commission as Exhibit 99.1 attached\nherewith and is incorporated herein by reference.\n\n
Item 9.01 FINANCIAL STATEMENTS AND\nEXHIBITS\n\n
(d) Exhibits\n\n
The following is filed as an Exhibit to\nthis Report.\n\n
\n
\n\n \n | Exhibit No. | \n | \n Description\nof Exhibit | \n
\n\n \n | | \n | \n | \n
\n\n\n \n 99.1 | \n | \n Press Release of Brady Corporation, dated June 18, 2010, relating to\nthe appointment of Gary S. Balkema. | \n \n\n
\n\n\n \n\n
2\n\n\n\n
\n
\n\n\n\n\n
\n\n\nSIGNATURE\n\n
Pursuant to the requirements of the\nSecurities Exchange Act of 1934, the Registrant has duly caused this report to\nbe signed on its behalf by the undersigned hereunto duly authorized.\n\n
BRADY CORPORATION\n\n
Date: June 24, 2010\n\n
/s/ Thomas J. Felmer
Thomas J. Felmer\n
\nSenior Vice President &
\nChief Financial Officer\n\n
\n\n
3\n\n\n\n
\n
\n\n\n\nEXHIBIT INDEX\n
\n
\n\n\n \n | | \n | \n | \n
\n\n\n \n | \n EXHIBIT
\nNUMBER \n | \n | \n
\nDESCRIPTION | \n
\n \n | \n \n | \n | \n | \n
\n\n \n 99.1 | \n | \n Press Release of Brady Corporation, dated June 18, 2010, relating to\nthe appointment of Gary S. Balkema. | \n \n\n\n
\n
\n\n
4\n\n\n\n
\n\nExhibit 99.1\n\n\n\n\n\nEXHIBIT 99.1\n\n
For More Information Contact:\n
\nCarole Herbstreit (414) 438-6882\n\n
Gary S. Balkema to join Brady\nCorporation Board of Directors.\n\n
MILWAUKEE (June 18,\n2010)—Gary S. Balkema will join the Board of Directors of Brady\nCorporation (NYSE:BRC), effective July 19, 2010. Balkema, 54, is president\nof the Worldwide Consumer Care Division for Bayer AG and a member of the Bayer\nHealthCare Executive Committee.\n\n
Balkema joined Bayer\nin 1994 as president of Consumer Care USA. In 2000, he was appointed general\nmanager of the Consumer Care Business Group, which ranks among the top consumer\nhealthcare companies in the world, operating in more than 140 countries. His\nresponsibilities included strategic direction and leadership for the business\ngroup worldwide. Prior to Bayer, Balkema was vice president and general manager\nof the Shulton Division and head of the Lederle Consumer Health Division, both\nat American Cyanamid, with leadership responsibility for manufacturing, sales,\nproduct management and strategic business management. He holds degrees in\nbusiness administration and aeronautical science from Nathaniel Hawthorne\nCollege and received his MBA from Fairleigh Dickinson University.\n\n
“Gary will be a\ngreat addition to Brady’s board,” said Conrad Goodkind, lead\nindependent director and chair of Brady’s corporate governance Committee.\n“Over the last 15 years, sales of Bayer’s Consumer Care group\nhave quintupled to more than $3.8 billion through several large\nacquisitions and substantial organic growth. Gary’s breadth of business\nexperience, including large-scale integration of new businesses and strategic\nmarketing, will be a real asset as Brady continues to grow,” Goodkind\nsaid.\n\n
“While\nBrady’s past track record and vision for future growth coupled with a\nsound balance sheet is attractive in its own right, after gaining a deeper\nunderstanding of Brady’s breadth of product line, customer segments, and\nvalue proposition delivered through its diverse businesses, I am energized and\neager to begin working with the Brady leadership team and other directors on\nthe board to take Brady to the next level,” said Balkema.\n\n
The Bayer Group is a\nglobal enterprise with core competencies in the fields of healthcare, nutrition\nand high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is a\nleading diversified healthcare company based in Leverkusen, Germany. The\ncompany combines the global activities of the Animal Health, Bayer Schering\nPharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim\nis to discover, manufacture and market products that will improve human and\nanimal health worldwide.\n\n
Brady Corporation is\nan international manufacturer and marketer of complete solutions that identify\nand protect premises, products and people. Its products help customers increase\nsafety, security, productivity and performance and include high-performance\nlabels and signs, safety devices, printing systems and software, and precision\ndie-cut materials. Founded in 1914, the company has more than 500,000 customers\nin electronics, telecommunications, manufacturing, electrical, construction,\neducation, medical and a variety of other industries. Brady is headquartered in\nMilwaukee and employs about 7,000 people at operations in the Americas, Europe\nand Asia/Pacific. Brady’s fiscal 2009 sales were approximately\n$1.2 billion.\n\n
More information is\navailable on the Internet at www.bradycorp.com.\n\n
##\n\n
\n\n
\n\n\n\n","error":null}